m.restrepo

TL2 · Cork

Contributes reviews on supplier material. Based in Cork.

Joined 26 September 2025 · last posted 2d

67 posts, newest first. Showing up to 150.

Stepping down deliberately, and how to do it without losing progress — what changed since Replied, post #98 · Practice › Dosing & titration · 26 Jul 2026 · 18 likes Stepping down deliberately: the withdrawal trials show that stopping is followed by regain. The step-down literature is thinner. The conservative assumption is that…
What the GIP component of tirzepatide is thought to contribute, and how confident we can… Replied, post #18 · Compounds › Tirzepatide · 25 Jul 2026 · 2 likes Everything in post #16 holds. The case it does not cover is the one I have. Titration schedules for tirzepatide have more dose steps than semaglutide partly because the…
Common supplements people ask about, assessed one at a time Replied, post #57 · Practice › Interactions · 17 Jul 2026 · 0 likes What I would check first on common supplements is whether the thing being measured moved or whether the way of measuring it moved. Those look identical in a graph.
Blinding yourself: practical methods and their limits Replied, post #41 · Research Methods › N-of-1 designs · 9 Jul 2026 · 4 likes Post #38 answers the question as asked. The question underneath it is different. Blinding yourself is worth one more sentence than it usually gets, and the sentence is…
What I would want from a home test that does not exist yet Replied, post #32 · Analytics › Home & field testing · 9 Jul 2026 · 18 likes Post #28 put the caveat in the right place and I want to underline it. Ultraviolet absorbance at 280 nanometres estimates concentration for peptides containing aromatic…
Journal club: SUSTAIN 6 and its retinopathy signal Replied, post #33 · Evidence › Journal club · 7 Jul 2026 · 22 likes Where the group cannot agree, record the disagreement rather than resolving it by seniority. The recorded disagreement is more honest and more useful later. The…
Tracking a shortage from primary sources rather than rumour Replied, post #87 · Access › Shortages · 6 Jul 2026 · 27 likes Post #85 put the caveat in the right place and I want to underline it. Reading this tracking a shortage thread as someone who came in with a fixed view: the third and…
[2026 update] Second opinions: how to seek one without burning the first Replied, post #2 · marked as the solution · Clinical › Prescriber conversations · 3 Jul 2026 · 14 likes Worth separating two things that the opening post runs together. Take the actual numbers and the actual dates. A printed table beats a description and takes the first…
Prescription requirements and telehealth models — a second dataset Replied, post #70 · Sourcing › Regulatory · 18 Jun 2026 · 11 likes On post #66 — agreed on the reasoning, with one qualification. Agreed on Prescription requirements and telehealth models, with one qualification that I think matters.…
Pooling trials with different estimands Replied, post #8 · Evidence › Meta-analyses · 5 Jun 2026 · 7 likes Overlapping populations across included trials inflate the apparent sample size. It happens more than people expect where the same programme reports multiple papers.…
Second pass at: When your prescriber and the evidence disagree Replied, post #29 · Clinical › Prescriber conversations · 31 May 2026 · 3 likes Clarifying indication: if a compound is approved for diabetes but you have obesity without diabetes, clarify whether your clinician considers this off-label use and…
Follow-up: Sleep quality changes during weight loss Replied, post #16 · Wellbeing › Sleep · 5 May 2026 · 15 likes Right, and stated more narrowly than I would have dared to state it.
Coming back to: Washout: how long is long enough, and for what purpose Replied, post #115 · Pharmacology › Pharmacokinetics · 22 Apr 2026 · 17 likes Post #112 is the version of this I will quote in future. One addition. Adding a small correction to the Washout summary above rather than a disagreement with it. The…
[2026 update] 0.3 mL versus 0.5 mL versus 1 mL barrels: resolution matters Replied, post #40 · Devices › Syringes & needles · 18 Apr 2026 · 7 likes The documentation on 0.3 ml versus 0.5 ml is better than this thread and I say that as someone who has posted in the thread.
Pregnancy and pregnancy planning: contraindication and washout Replied, post #78 · Clinical › Special populations · 19 Mar 2026 · 2 likes Building on post #76 rather than restating it. A note on scope: what I am saying about pregnancy and pregnancy planning applies to the case in the first post and I…
A site rotation scheme that is easy enough to actually follow Replied, post #21 · Practice › Administration · 16 Mar 2026 · 2 likes Picking up post #20: that is the part I would want checked first. An observation about site rotation scheme that I cannot explain and am posting anyway, on the…
MHRA statements, read directly Replied, post #83 · Regional › UK & Ireland · 6 Feb 2026 · 0 likes Whatever the answer on MHRA statements turns out to be, the method for getting there is the same: state the assumption, do the arithmetic in public, invite the…
Coming back to: Washout: how long is long enough, and for what purpose Replied, post #32 · Pharmacology › Pharmacokinetics · 3 Feb 2026 · 16 likes The arithmetic in post #31 is right; the assumption feeding it is the part to check. Area under the curve is the exposure measure that matters for most effects in this…
Reading an interaction checker output critically Replied, post #102 · Practice › Interactions · 26 Jan 2026 · 29 likes Adding the measurement that post #99 says would settle it. The most useful reply I ever got about reading an interaction checker output was a request to state my units.…
Second pass at: Pregnancy and pregnancy planning: contraindication and washout Replied, post #8 · Clinical › Special populations · 20 Jan 2026 · 12 likes Confirming post #5 from a second method, which matters more than confirming it from a second person. Having read the whole Pregnancy and pregnancy planning thread…
Older adults, sarcopenia risk, and the trade-off nobody quantifies Replied, post #61 · Clinical › Special populations · 27 Dec 2025 · 2 likes Worth separating two things that post #59 runs together. I would rather this thread reach "we do not know" about older adults than reach a confident answer that nobody…
Amylin analogue mechanism: satiety signalling separate from GLP-1 — does this still hold? Replied, post #24 · Compounds › Cagrilintide & amylin analogues · 26 Dec 2025 · 0 likes Everything in post #21 holds. The case it does not cover is the one I have. The monoisotopic mass sits near 3749.9 Da, and the same caveat applies as everywhere else: a…
Why semaglutide solutions can look faintly opalescent and when that matters Replied, post #48 · Compounds › Semaglutide · 25 Dec 2025 · 10 likes The arithmetic in post #45 is right; the assumption feeding it is the part to check. Semaglutide versus liraglutide in STEP 8: semaglutide produced greater weight…
Reused chromatograms across lots: how to spot it — what changed since Replied, post #7 · Analytics › COA interpretation · 23 Dec 2025 · 0 likes Reporting rather than recommending, on Reused chromatograms across lots. What happened is above. Whether it should have is a different question and not one I am…
Revisiting: Language barriers in accessing a prescription abroad Replied, post #11 · Access › International · 13 Dec 2025 · 14 likes If you are new and reading this thread for the answer to Language barriers in accessing: the answer is conditional, the conditions are in the third reply, and the rest…
Tracking a preprint to publication: a worked example Replied, post #45 · Evidence › Preprints · 4 Dec 2025 · 6 likes Helpful, and easy to find again, which is half of what a good reply is.
Half-life, steady state, and accumulation worked through — a second dataset Replied, post #27 · Pharmacology › Pharmacokinetics · 27 Nov 2025 · 30 likes Post #23 put the caveat in the right place and I want to underline it. Trying to state the Half-life position in a way that someone who disagrees would recognise as…
Severe gastroparesis and why this class is a poor fit — one year on Replied, post #12 · Safety › Contraindications · 26 Nov 2025 · 15 likes Helpful, and easy to find again, which is half of what a good reply is.
Lurking for two months before posting: was that the right call? Replied, post #49 · Start Here › Welcome · 19 Nov 2025 · 0 likes Trust levels accumulate over time and they give you access to small things like the ability to edit your own posts without a timestamp. They are not a status symbol and…
Pen dose counters: what a click does and does not guarantee Replied, post #29 · Devices › Pens & autoinjectors · 14 Nov 2025 · 0 likes Post #28 answers the question as asked. The question underneath it is different. Research-use-only material does not come in a metering device, and adapting one is…
What a purity-only report leaves out Replied, post #56 · Sourcing › Independent verification · 22 Oct 2025 · 0 likes Purity-only is a good example of a question where the honest answer is boring and the interesting answers are unsupported. I would go with boring.
Where impurities in solid-phase peptide synthesis come from Replied, post #14 · Analytics › Impurities & related substances · 18 Oct 2025 · 21 likes On impurities in solid-phase peptide synthesis I would separate what is worth knowing from what is worth acting on. The first list is long and the second is short, and…
Thyroid function tests during substantial weight change Replied, post #93 · Clinical › Bloodwork · 12 Oct 2025 · 0 likes One more thing on thyroid function tests during substantial that took me far too long to see: the two figures people quote are not measuring the same quantity. Once you…
Coming back to: Over-dilution: when your dose falls below one readable graduation Replied, post #61 · Practice › Reconstitution · 28 Sep 2025 · 29 likes Good question, well framed, and I would like to see it answered properly.
Reporting a disappointing outcome, and why it belongs here Replied, post #30 · Outcomes › Progress reports · 27 Sep 2025 · 19 likes Post #28 is right about the mechanism and I think understates the practical bit. Rate of change: reporting progress as "lost 5 kg in 12 weeks" is more useful than…
Why one laboratory's 98.4% and another's 96.1% may not contradict Replied, post #23 · Analytics › Method validation · 26 Sep 2025 · 0 likes Coming back to post #21, because the follow-up matters more than the original answer. Stability-indicating method: one that can separate a compound from its degradation…
Coming back to: Resolution and tailing factor: real acceptance criteria Replied, post #68 · Analytics › HPLC & UHPLC · 13 Sep 2025 · 0 likes A chromatogram image at a resolution where you can see peak shape but not baseline detail is worth having and is not the same as the data. Ask for the integration table…
Follow-up: Journal club: orforglipron phase 2 and the non-peptide question Replied, post #72 · Evidence › Journal club · 3 Sep 2025 · 0 likes Adding the measurement that post #71 says would settle it. Where I have landed on orforglipron phase 2, having got it wrong once in public: the direction is clear, the…
What I would record differently if I started again — the long version Replied, post #6 · Outcomes › Progress reports · 4 Aug 2025 · 14 likes If a pattern survives a rolling-mean treatment it is worth explaining. Most do not, and that is the useful finding.
A ten-fold dose error caught before injection Replied, post #75 · Devices › Syringes & needles · 2 Aug 2025 · 13 likes Reading rather than contributing, but this is the most useful thread I have found on it.
Coming back to: Amylin analogue mechanism: satiety signalling separate from GLP-1 Replied, post #31 · Compounds › Cagrilintide & amylin analogues · 22 Jul 2025 · 21 likes Amylin analogue mechanism: I would want to see the raw numbers rather than the summary before agreeing. Summaries lose exactly the information that would settle this.
Revisiting: Filing a first vendor report: a worked example Replied, post #2 · Sourcing › Vendor reports · 7 Jul 2025 · 13 likes Report the certificate figure alongside the independent one. The comparison is the point and it is the part most often omitted. I have changed my mind on this once…
Coming back to: Resolution and tailing factor: real acceptance criteria Replied, post #3 · Analytics › HPLC & UHPLC · 6 Jul 2025 · 0 likes Useful. I had the fact and not the reason, which turns out to be the important half.
[2026 update] An appeal that failed, and what I would do differently Replied, post #75 · Access › Insurance & coverage · 12 Jun 2025 · 31 likes I read post #71 twice before replying, because I had assumed the opposite. On appeal I would separate what is worth knowing from what is worth acting on. The first list…
Follow-up: Tracking intake honestly when appetite is absent Replied, post #46 · Nutrition & Training › Protein & intake · 9 Jun 2025 · 3 likes That is clearer than the version I had in my head. Thank you.
Journal club: the CagriSema phase 2 combination paper — a second dataset Replied, post #22 · Evidence › Journal club · 1 Jun 2025 · 0 likes Quoting the sentence rather than paraphrasing it changes the discussion. Paraphrase is where a claim quietly becomes stronger than the paper made it. The answer changed…
Why one laboratory's 98.4% and another's 96.1% may not contradict Replied, post #7 · Analytics › Method validation · 21 May 2025 · 31 likes I read post #5 twice before replying, because I had assumed the opposite. Stability-indicating method: one that can separate a compound from its degradation products.…
Research-use-only labelling: what it means and what it does not — the long version Replied, post #143 · Sourcing › Regulatory · 3 May 2025 · 0 likes Post #141 describes the usual case. This is about the unusual one. The reason Research-use-only labelling keeps being re-asked is that the answer is conditional and…
Fibre intake when total intake falls, and the constipation link Replied, post #54 · Nutrition & Training › Protein & intake · 15 Apr 2025 · 0 likes Fibre intake was covered in the wiki last year and the page has a review date on it, which is a better starting point than my memory of a thread.
A 5 mg vial and a 0.25 mg dose: the arithmetic in full — what changed since Replied, post #49 · Practice › Reconstitution · 13 Apr 2025 · 0 likes Adding the measurement that post #48 says would settle it. Small correction to my own earlier position on 5 mg vial. I had the units the wrong way round, which changes…
Follow-up: What other technical communities get right that we do not Replied, post #65 · Lounge › Off topic · 12 Apr 2025 · 11 likes Newer drugs and mechanisms: when a new drug launches or a new mechanism is discovered, the Lounge is a place to discuss the news and speculate before hard data exists.…
One lot is one lot: when a report becomes a pattern — the long version Replied, post #23 · Sourcing › Vendor reports · 15 Mar 2025 · 27 likes Good question, well framed, and I would like to see it answered properly.
What the published dose-response for semaglutide actually looks like above 2.4 mg — a… Replied, post #66 · Compounds › Semaglutide · 16 Feb 2025 · 6 likes On post #62 — agreed on the reasoning, with one qualification. STEP 1 and STEP 4 are two different questions. The first asks what happens when treatment is added; the…
Journal club: STEP 4 and what a withdrawal design can prove — one year on Replied, post #30 · Evidence › Journal club · 31 Jan 2025 · 4 likes Sessions on negative or null results are consistently the most instructive and the hardest to get anyone to attend.
[2026 update] Journal club: SURPASS-2 and the semaglutide 1 mg comparator Replied, post #71 · Evidence › Journal club · 25 Dec 2024 · 17 likes Confirming post #68 from a second method, which matters more than confirming it from a second person. On SURPASS-2: the maintained page in the documentation commons…
Follow-up: Tirzepatide's shorter half-life and its one practical consequence Replied, post #98 · Compounds › Tirzepatide · 20 Dec 2024 · 9 likes Where I part company with post #96, and it is a narrow parting. Gastrointestinal effects were comparable in character to the GLP-1 monoagonists across the programme.…
Molecular mass of semaglutide and why the figure differs between sources — does this… Replied, post #6 · Compounds › Semaglutide · 18 Dec 2024 · 27 likes Good question, well framed, and I would like to see it answered properly.
A promotion I argued against, and why I lost Replied, post #14 · Documentation › Doc review · 26 Nov 2024 · 3 likes Post #11 is the version of this I will quote in future. One addition. Review of promoted topics: when a topic is nominated for promotion to a maintained documentation…
Follow-up: Recovery when intake is low: what to cut first Replied, post #22 · Nutrition & Training › Resistance training · 14 Nov 2024 · 30 likes The most useful reply I ever got about Recovery was a request to state my units. It sounds like pedantry and it has saved me twice.
Time to steady state after a dose increase Replied, post #58 · Pharmacology › Pharmacokinetics · 4 Nov 2024 · 0 likes This follows post #55 rather than contradicting it. Fasting requirement for oral semaglutide: food and large fluid volumes reduce absorption. The fasting window (30…
When a red flag was a misunderstanding, and the retraction Replied, post #34 · Sourcing › Red flags · 14 Oct 2024 · 12 likes I read the earlier replies on red flag twice before writing this, because I had assumed the opposite and wanted to be sure I was disagreeing with what was said rather…
Blind submission and why it changes minds Replied, post #66 · Sourcing › Independent verification · 20 Sep 2024 · 0 likes Medutest: combined purity and identity reporting. Appears throughout vendor documentation. Where a submission has been blind we note it because blind results are worth…
Progressive overload when the scale is falling — one year on Replied, post #7 · Nutrition & Training › Resistance training · 26 Aug 2024 · 1 like I would be cautious about generalising from the Progressive overload example above. It is a good example. It is one example.
Chronic kidney disease and the FLOW result Replied, post #10 · Clinical › Comorbidities · 12 Aug 2024 · 1 like One more thing on chronic kidney disease that took me far too long to see: the two figures people quote are not measuring the same quantity. Once you notice that, the…
Circumference measurements as a poor man's composition estimate Replied, post #36 · Outcomes › Body composition · 2 Aug 2024 · 6 likes I have no financial interest in anything named in this thread and I want to say so before I comment on circumference measurements, because it is the sort of subject…
Pancreatitis history and the risk calculus — a second dataset Replied, post #3 · Safety › Contraindications · 26 Jul 2024 · 0 likes On the opening post — agreed on the reasoning, with one qualification. Allergy to the specific compound: true allergy is rare but possible. Any prior allergic reaction…
How to ask for a dose change without antagonising anyone Replied, post #5 · Clinical › Prescriber conversations · 13 Jul 2024 · 6 likes I read post #4 twice before replying, because I had assumed the opposite. Bringing a record of symptoms with dates and severities makes an assessment materially easier…